ArtNr |
HY-14644A-10mM |
Hersteller |
MedChem Express
|
CAS-Nr. |
870087-36-8 |
Menge |
10mM/1mL |
Quantity options |
100 mg
10mM/1mL
10 mg
50 mg
5 mg
|
Kategorie |
|
Typ |
Inhibitors |
Specific against |
other |
Purity |
99.83 |
Formula |
C25H34N6O8S2 |
Citations |
bioRxiv. 2023 Aug 12.<br/>bioRxiv. 2024 Jan 23.<br/>Biomaterials. 2022 Jun;285:121509.<br/>bioRxiv. 2020 Apr 21;2020.04.21.053058. <br/>bioRxiv. 2023 Apr 28.<br/>bioRxiv. 2023 Aug 12.<br/>bioRxiv. 2023 Aug 28.<br/>bioRxiv. 2024 May 10.<br/>biorxiv. 2024 May 27.<br/>Biotechnol J. 2022 Dec 7;e2200147.<br/>Br J Cancer. 2020 Aug;123(4):542-555.<br/>Cancer Lett. 2023 Oct 6:216435.<br/>Cell Mol Life Sci. 2016 Dec;73(24):4717-4737. <br/>Commun Biol. 2022 Mar 24;5(1):262.<br/>J Biol Chem. 2022 Dec 6;102775.<br/>J Virol. 2021 Aug 18;JVI0097521.<br/>Mol Biol Cell. 2022 Jan 12;mbcE21060309.<br/>Nat Commun. 2020 Mar 27;11(1):1620.<br/>PLoS Pathog. 2023 Feb 24;19(2):e1011202.<br/>Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2307423120.<br/>Proc Natl Acad Sci U S A. 2024 May 21;121(21):e2403685121.<br/>Sci Adv. 2022 Jul 22;8(29):eabn1440.<br/>Sci Adv. 2023 Oct 13;9(41):eadh1134.<br/>SSRN. 2024 Jan 26.<br/>Theranostics. 2020 Mar 4;10(9):3925-3938.<br/>Viruses. 2021 Jun 28;13(7):1255.<br/>Viruses. 2023 Jun 12, 15(6), 1353.<br/>[1]Wada Y, et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007 Feb 1;109(3):1156-64.<br/>[2]Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.IDrugs. 2007 Jan;10(1):53-9.<br/>[3]Keino H, et al. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122. |
Smiles |
CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC4=CC=CC=N4)=N2)=C1.CS(=O)(O)=O.CS(=O)(O)=O |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
STA 5326 (mesylate); LAM-002A; AIT-101 (mesylate) |
Similar products |
870087-36-8 |
Lieferbar |
|
Product Description |
Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively[1]. Apilimod is a potent and highly selective PIKfyve inhibitor. |
StorageTemperature |
4°C (Powder, sealed storage, away from moisture) |
Shipping |
Room Temperature |
Manufacturers Applications |
COVID-19-immunoregulation |
MolecularWeight |
610.70 |
Clinical Information |
Phase 2 |
Manufacturers Research Area |
Inflammation/Immunology |
Solubility |
DMSO : 12.5 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic) |
Target |
Interleukin Related; PIKfyve |
Manufacturers Target |
Interleukin Related; PIKfyve |
Isoform |
IL-12; IL-23; IL-4; IL-5; IL-8 |
Manufacturers Pathway |
Immunology/Inflammation; PI3K/Akt/mTOR |
Manufacturers Product type |
Reference compound |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.